Cargando…
Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone
BACKGROUND: Poor control of type 2 diabetes results in substantial long-term consequences. Studies of new diabetes treatments are rarely designed to assess mortality, complication rates and costs. We sought to estimate the long-term consequences of liraglutide and rosiglitazone both added to glimepi...
Autores principales: | , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2667489/ https://www.ncbi.nlm.nih.gov/pubmed/19245711 http://dx.doi.org/10.1186/1475-2840-8-12 |
_version_ | 1782166134388162560 |
---|---|
author | Sullivan, Sean D Alfonso-Cristancho, Rafael Conner, Chris Hammer, Mette Blonde, Lawrence |
author_facet | Sullivan, Sean D Alfonso-Cristancho, Rafael Conner, Chris Hammer, Mette Blonde, Lawrence |
author_sort | Sullivan, Sean D |
collection | PubMed |
description | BACKGROUND: Poor control of type 2 diabetes results in substantial long-term consequences. Studies of new diabetes treatments are rarely designed to assess mortality, complication rates and costs. We sought to estimate the long-term consequences of liraglutide and rosiglitazone both added to glimepiride. METHODS: To estimate long-term clinical and economic consequences, we used the CORE diabetes model, a validated cohort model that uses epidemiologic data from long-term clinical trials to simulate morbidity, mortality and costs of diabetes. Clinical data were extracted from the LEAD-1 trial evaluating two doses (1.2 mg and 1.8 mg) of a once daily GLP-1 analog liraglutide, or rosiglitazone 4 mg, on a background of glimepiride in type 2 diabetes. CORE was calibrated to the LEAD-1 baseline patient characteristics. Survival, cumulative incidence of cardiovascular, ocular and renal events and healthcare costs were estimated over three periods: 10, 20 and 30 years. RESULTS: In a hypothetical cohort of 5000 patients per treatment followed for 30 years, liraglutide 1.2 mg and 1.8 mg had higher survival rates compared to the group treated with rosiglitazone (15.0% and 16.0% vs. 12.6% after 30 years), and fewer cardiovascular, renal, and ocular events. Cardiovascular death rates after 30 years were 69.7%, 68.4% and 72.5%, for liraglutide 1.2 mg, 1.8 mg, and rosiglitazone, respectively. First and recurrent amputations were lower in the rosiglitazone group, probably due to a 'survival paradox' in the liraglutide arms (number of events: 565, 529, and 507, respectively). Overall cumulative costs per patient, were lower in both liraglutide groups compared to rosiglitazone (US$38,963, $39,239, and $40,401 for liraglutide 1.2 mg, 1.8 mg, and rosiglitazone, respectively), mainly driven by the costs of cardiovascular events in all groups. CONCLUSION: Using data from LEAD-1 and epidemiologic evidence from the CORE diabetes model, projected rates of mortality, diabetes complications and healthcare costs over the long term favor liraglutide plus glimepiride over rosiglitazone plus glimepiride. TRIAL REGISTRATION: LEAD-1 NCT00318422; LEAD-2 NCT00318461; LEAD-3 NCT 00294723; LEAD-4 NCT00333151; LEAD-5 NCT00331851; LEAD-6 NCT00518882. |
format | Text |
id | pubmed-2667489 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-26674892009-04-10 Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone Sullivan, Sean D Alfonso-Cristancho, Rafael Conner, Chris Hammer, Mette Blonde, Lawrence Cardiovasc Diabetol Original Investigation BACKGROUND: Poor control of type 2 diabetes results in substantial long-term consequences. Studies of new diabetes treatments are rarely designed to assess mortality, complication rates and costs. We sought to estimate the long-term consequences of liraglutide and rosiglitazone both added to glimepiride. METHODS: To estimate long-term clinical and economic consequences, we used the CORE diabetes model, a validated cohort model that uses epidemiologic data from long-term clinical trials to simulate morbidity, mortality and costs of diabetes. Clinical data were extracted from the LEAD-1 trial evaluating two doses (1.2 mg and 1.8 mg) of a once daily GLP-1 analog liraglutide, or rosiglitazone 4 mg, on a background of glimepiride in type 2 diabetes. CORE was calibrated to the LEAD-1 baseline patient characteristics. Survival, cumulative incidence of cardiovascular, ocular and renal events and healthcare costs were estimated over three periods: 10, 20 and 30 years. RESULTS: In a hypothetical cohort of 5000 patients per treatment followed for 30 years, liraglutide 1.2 mg and 1.8 mg had higher survival rates compared to the group treated with rosiglitazone (15.0% and 16.0% vs. 12.6% after 30 years), and fewer cardiovascular, renal, and ocular events. Cardiovascular death rates after 30 years were 69.7%, 68.4% and 72.5%, for liraglutide 1.2 mg, 1.8 mg, and rosiglitazone, respectively. First and recurrent amputations were lower in the rosiglitazone group, probably due to a 'survival paradox' in the liraglutide arms (number of events: 565, 529, and 507, respectively). Overall cumulative costs per patient, were lower in both liraglutide groups compared to rosiglitazone (US$38,963, $39,239, and $40,401 for liraglutide 1.2 mg, 1.8 mg, and rosiglitazone, respectively), mainly driven by the costs of cardiovascular events in all groups. CONCLUSION: Using data from LEAD-1 and epidemiologic evidence from the CORE diabetes model, projected rates of mortality, diabetes complications and healthcare costs over the long term favor liraglutide plus glimepiride over rosiglitazone plus glimepiride. TRIAL REGISTRATION: LEAD-1 NCT00318422; LEAD-2 NCT00318461; LEAD-3 NCT 00294723; LEAD-4 NCT00333151; LEAD-5 NCT00331851; LEAD-6 NCT00518882. BioMed Central 2009-02-26 /pmc/articles/PMC2667489/ /pubmed/19245711 http://dx.doi.org/10.1186/1475-2840-8-12 Text en Copyright © 2009 Sullivan et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Investigation Sullivan, Sean D Alfonso-Cristancho, Rafael Conner, Chris Hammer, Mette Blonde, Lawrence Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone |
title | Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone |
title_full | Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone |
title_fullStr | Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone |
title_full_unstemmed | Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone |
title_short | Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone |
title_sort | long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone |
topic | Original Investigation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2667489/ https://www.ncbi.nlm.nih.gov/pubmed/19245711 http://dx.doi.org/10.1186/1475-2840-8-12 |
work_keys_str_mv | AT sullivanseand longtermoutcomesinpatientswithtype2diabetesreceivingglimepiridecombinedwithliraglutideorrosiglitazone AT alfonsocristanchorafael longtermoutcomesinpatientswithtype2diabetesreceivingglimepiridecombinedwithliraglutideorrosiglitazone AT connerchris longtermoutcomesinpatientswithtype2diabetesreceivingglimepiridecombinedwithliraglutideorrosiglitazone AT hammermette longtermoutcomesinpatientswithtype2diabetesreceivingglimepiridecombinedwithliraglutideorrosiglitazone AT blondelawrence longtermoutcomesinpatientswithtype2diabetesreceivingglimepiridecombinedwithliraglutideorrosiglitazone |